

**Workshop program „Tumor immunology” at the 04<sup>th</sup> of May 2017,  
Venue: University Hospital (Halle-Kroellwitz), Ernst-Grube-Straße 40, 06120 Halle, Building 6, Lecture Hall**

No.	Speaker	Location	Title	Time
<b>Introduction: Barbara Seliger (Halle)</b>				
<b>News of tumor immunology - Chair: Elfriede Nößner (Munich) / Marc Schmitz (Dresden)</b>				<b>12.00 – 12.15</b>
1	Subbarayan, Karthik	Halle, D	Immune modulatory effects of biglycan on tumor cells	12.15 – 12.30
2	Grünberg, Mario	Köthen, D	Kallikrein-related peptidases are potent activators of the CC-chemokine CCL14	12.30 – 12.45
3	Ansems, Marleen	Nijmegen, NL	Nur77 deficiency alters dendritic cell function	12.45 – 13.00
4	Wuerfel, Franziska	Erlangen, D	Immune modulating receptors inhibit adaptive immune response in breast cancer	13.00 – 13.15
5	Eisel, David	Heidelberg, D	Antigen-specific interaction with activated CD4 <sup>+</sup> T cells induces M1 associated gene expression in M2 polarized macrophages	13.15 – 13.30
6	Siska, Peter	Regensburg, D	Mitochondrial dysregulation and glycolytic insufficiency impair function of CD8 <sup>+</sup> T cells infiltrating human renal cell carcinoma	13.30 – 13.45
7	Legscha, Kevin	Mainz, D	p53 isoform delta133: a new transcriptional enhancer of T cell effector function	13.45 – 14.00
8	Ali, Muhammad	Oslo, NOR	Neo-antigenic and immune cell profiling of follicular lymphoma after <i>in situ</i> immunotherapy	14.00 – 14.15
9	Ahmetlić, Fatima	Munich, D	The role of T cells for the therapeutic effect of immune checkpoint inhibitors in a murine model of B cell lymphoma	14.15 – 14.30
10	de Waard, Antonius	Amsterdam, NL	Tumor glycolipids determine immunogenicity by modulating accessibility of immune modulating surface proteins	14.30 – 14.45
11	Boehnert, Volker	Bonn, D	A whole cell vaccine in a transplantable model of ovarian cancer leads to persisting immunity	14.45 – 15.00
<b>Coffee break 15.00 – 15.30</b>				
<b>Methods and more news - Chair: Claudia Wickenhauser (Halle) / Stefan Eichmüller (Heidelberg)</b>				
12	Golumba-Nagy, Viktoria	Cologne, D	Making T cells more resistant to repression: CAR modified T cells modulate their environment	15.30 – 15.45
13	Stump, Julia	Munich, D	Increased CD8 <sup>+</sup> T cell infiltrates and PD-L1 positive cells in NSCLC correlate with better patient's survival	15.45 – 16.00
14	Tunger, Antje	Dresden, D	Generation of high-avidity, WT1-reactive CD8 <sup>+</sup> cytotoxic T cell clones with anti-leukemic activity by streptamer technology	16.00 – 16.15
15	Bacic, Biserka	Diessen, D	Spatially resolved, multiplexed digital characterization of protein and RNA expression in FFPE tissue sections	16.15 – 16.30
16	Wendik, Björn	Rodgau, D	Deciphering the biology that drives response to immunotherapy	16.30 – 16.45
17	Steffen Panzner	Halle, D	Delivery of mRNA using the Viromer® system	16.45 – 17.00
18	Lowy, Camille	Heidelberg, D	Patient stratification and therapy response prediction for anti-PD-1 therapy using plasma biomarker signature	17.00 – 17.15
19	Respa, Annedore	Hertfordshire, GBR	Validation of novel continuous live-cell assays for immune cell activation and killing of blood cell cancers	17.15 – 17.30
20	Kleen, Thomas	Miami, USA	Epigenetic markers of immune cells used for immune monitoring	17.30 – 17.45
21	Röder, Heinrich	Boulder, USA	Primary checkpoint resistance from circulating proteins	17.45 – 18.00
<b>Summary: Michael Bachmann (Dresden)</b>				

**We thank our sponsors:**

Astra Zeneca GmbH (1.500 €), Becton Dickinson GmbH, Biodesix, Bristol-Myers Squibb (3.000 €), CureVac, CDDF (Cancer Drug Development Forum) (2.500 €), City of Halle, CureVac (2.000 €), Deutsche Forschungsgemeinschaft (DFG), Deutsche Gesellschaft für Immunologie (DGfI), Epiontis, Essen BioScience Ltd, Life Science Solutions PerkinElmer, Lipocalyx GmbH, Merck Serono GmbH (750 €), Miltenyi Biotec GmbH, nanoString Technologies, Novartis Pharma GmbH (750 €), Pfizer Pharma GmbH (1.000 €), Qiagen GmbH, Sarstedt, Sciomics GmbH, SERVA GmbH, SITC